Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
12 hedge funds and large institutions have $1.5M invested in Yield10 Bioscience, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
20% more funds holding
Funds holding: 10 → 12 (+2)
1.59% more ownership
Funds ownership: 9.06% → 10.65% (+1.6%)
14% less capital invested
Capital invested by funds: $1.74M → $1.5M (-$243K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$90.4K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$79.3K |
| 3 |
Renaissance Technologies
New York
|
+$72.9K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.8K |
| 5 |
VF
Virtu Financial
New York
|
+$42.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$38K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$32K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$24K |
YTEN Hedge Fund Activity: Q2 2018 in Review
12 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q2 2018, worth a combined $1.5M — down 14% from $1.74M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new YTEN positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $90.4K. The largest seller was Jane Street, exiting entirely with an estimated $38K sold.
- 12 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q2 2018, up from 10 in Q1 2018.
- Funds reported $1.5M of Yield10 Bioscience, Inc. Common Stock stock for Q2 2018, down 14% quarter-over-quarter.
- 5 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q2 2018 and 3 closed out, a net change of +2 holders.
- The largest Yield10 Bioscience, Inc. Common Stock buyer in Q2 2018 was Geode Capital Management, an estimated $90.4K added.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q2 2018 was Jane Street, an estimated $38K sold.
Based on aggregated 13F filings for Q2 2018.